INDV Q1 2023 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$253M+22.2% YoY

Gross Profit

$214M84.6% margin

Operating Income

$57M22.5% margin

Net Income

$44M17.4% margin

EPS (Diluted)

$0.32

QoQ Revenue Growth

+4.5%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$42M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$1.7B

Stockholders' Equity

$72M

Cash & Equivalents

$588M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$253M	$207M	+22.2%
Gross Profit	$214M	$170M	+25.9%
Operating Income	$57M	$54M	+5.6%
Net Income	$44M	$41M	+7.3%